OpenEvidence reportedly eyes $200M raise at $20B valuation, signaling AI healthcare’s breakneck growth

OpenEvidence, an AI-powered clinical decision support platform, is reportedly raising $200 million at a $20 billion valuation, nearly six times its $3.5 billion valuation from July 2025. The company, used by over 40% of US physicians, has raised approximately $700 million in the past year from investors including Thrive Capital, Sequoia, and Nvidia. The potential valuation underscores surging venture capital interest in AI healthcare, with OpenEvidence's revenue multiple exceeding 130x based on reported $150 million in annual revenue.

OpenEvidence reportedly eyes $200M raise at $20B valuation, signaling AI healthcare’s breakneck growth The AI-powered medical platform has rocketed from $3.5 billion to potentially $20 billion in under a year, and the trajectory tells a bigger story about where venture capital is flowing. OpenEvidence, the Miami-based AI platform often described as “ChatGPT for doctors,” is reportedly considering raising $200 million at a $20 billion valuation. If confirmed, that would represent a nearly 6x increase from the company’s $3.5 billion valuation in July 2025, and a meaningful jump from the $12 billion it commanded just months ago. A fundraising pace that makes venture capitalists dizzy OpenEvidence has been on an absolute tear. The company raised approximately $700 million across several funding rounds in the past year alone. Its Series C in October 2025 brought in $200 million at a $6 billion valuation. Then, just three months later, a $250 million Series D pushed that number to $12 billion. The investor roster reads like a who’s who of Silicon Valley and beyond: Thrive Capital, DST Global, Sequoia, Google Ventures, Nvidia, and, notably, Mayo Clinic. What OpenEvidence actually does The platform provides AI-powered clinical decision support to healthcare professionals, pulling from peer-reviewed medical sources like the New England Journal of Medicine, JAMA, and NCCN oncology guidelines. More than 40% of US physicians reportedly use the platform across over 10,000 hospitals and medical centers. The company has also reported annual revenue reaching $150 million at one point. The company requires users to be verified medical professionals, which creates both a trust moat and a natural constraint on growth. Why this matters for the broader AI investment landscape OpenEvidence doesn’t touch crypto, blockchain, or digital assets. It’s a pure-play AI healthcare company. A $20 billion valuation for a company with $150 million in reported revenue implies a revenue multiple north of 130x. US healthcare spending runs into the trillions annually. What to watch: whether this $200 million raise actually closes, and at what valuation. If it comes in at or above $20 billion, it will cement OpenEvidence as one of the most valuable private AI companies globally. Disclosure: This article was edited by Editorial Team. For more information on how we create and review content, see our Editorial Policy https://cryptobriefing.com/editorial-policy/ .